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Abstract
Background
In order to retrieve useful information from scientific literature and electronic medical records
(EMR) we developed an ontology specific for Multiple Sclerosis (MS).
Methods
The MS Ontology was created using scientific literature and expert review under the Pro-
tégé OWL environment. We developed a dictionary with semantic synonyms and transla-
tions to different languages for mining EMR. The MS Ontology was integrated with other
ontologies and dictionaries (diseases/comorbidities, gene/protein, pathways, drug) into the
text-mining tool SCAIView. We analyzed the EMRs from 624 patients with MS using the MS
ontology dictionary in order to identify drug usage and comorbidities in MS. Testing compe-
tency questions and functional evaluation using F statistics further validated the usefulness
of MS ontology.
Results
Validation of the lexicalized ontology by means of named entity recognition-based methods
showed an adequate performance (F score = 0.73). The MS Ontology retrieved 80% of the
genes associated with MS from scientific abstracts and identified additional pathways tar-
geted by approved disease-modifying drugs (e.g. apoptosis pathways associated with
mitoxantrone, rituximab and fingolimod). The analysis of the EMR from patients with MS
identified current usage of disease modifying drugs and symptomatic therapy as well as co-
morbidities, which are in agreement with recent reports.
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Conclusion
The MS Ontology provides a semantic framework that is able to automatically extract infor-
mation from both scientific literature and EMR from patients with MS, revealing new patho-
genesis insights as well as new clinical information.
Introduction
To understand MS it is necessary to integrate information from several different sources using
advanced computational tools [1–3]. However, the first challenge to be met is to retrieve useful
information from the multiple sources available (structured databases, narrative text in scien-
tific articles, medical information in clinical notes) despite the different data standards and
qualities. Currently, a tremendous amount of information is available through the scientific lit-
erature (e.g. 62,364 articles on MS at PubMed by October 2014), a number that is steadily in-
creasing. Information retrieval is not the creation of new knowledge and for this reason it is
necessary to use specific tools to exploit this vast quantity of data. For this reason, the use of au-
tomated systems to retrieve information, which will scan scientific literature sources on the
basis of medical concepts, has gained much attention in the field of medical informatics, lead-
ing to the development of dedicated text-mining systems.
One-way of retrieving information from these complex sources is to use ontologies and
text-mining tools. In medical informatics, Ontology is a computational tool that represents
knowledge as a set of concepts (words) within a domain (e.g. MS), using a shared vocabulary
(dictionary) to denote the types, properties and interrelationships between such concepts
(symptoms, drugs, molecules, pathways, etc.) [4]. Ontologies have been used extensively to re-
trieve and integrate biological information (e.g. Gene Ontology), or medical information, such
as the Alzheimer's disease ontology, that enabled us to obtain additional information from
PubMed abstracts and electronic medical records (EMR) (e.g. identifying hypertension, diabe-
tes and stroke as the most common co-morbidities for AD) [5].
In this study we aimed to develop an ontology specific for MS for clinical and translational
research. Also, we envisage that in the near future they can be used at the clinical level to re-
trieve information from EMRs in order to design more tailored healthcare for
given populations.
Methods
Ethical Statement
This study was approved by the Ethical Committee of the Hospital Clinic of Barcelona, which
provided a waiver for the request of the patients’ written informed consent. All clinical investi-
gation have been conducted according to the principles expressed in the Declaration of
Helsinki
Electronic Health Records from patients with MS
We analyzed the EMRs of MS patients from the Hospital Clinic of Barcelona. The EMR system
at our center is at level 6 of the HIMSS category (http://www.himss.org/) since 2011. MS cases
were retrieved from the database of the MS center, or by using the ICD-9 code 340, or the key
words “Multiple Sclerosis” or “demyelinating disease” in the free text of the medical notes. We
identified 734 records from patients fulfilling this search criteria. Diagnosis was confirmed by a
MSOntology
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specialized neurologist (PV), making 624 MS cases available for analysis. Patients were exclud-
ed mainly because MS was cited as part of the differential diagnosis but the disease was not
confirmed. We also noted that the diagnosis of “Systemic Sclerosis” was included in the results
and thus, this diagnosis was introduced into subsequent searches as a specific exclusion criteria.
We collected all the notes from any physician who has ever participated in the patient’s care,
not only those of the neurologists, as well as discharge letters or emergency room letters, and
exported them as anonymized pdf files for further analysis. This study was approved by the
IRB of the Hospital Clinic of Barcelona, which provided a waiver for the request of the patients’
written informed consent.
Development of the MS ontology
The MS Ontology was constructed using the same approach as the AD ontology described pre-
viously [5]. Briefly, we used the Protege OWL editor (version 4.2; http://protege.stanford.edu)
to build the MS Ontology. A collection of terms and concepts related to MS were generated by
scanning various knowledge sources, such as scientific articles, the content of online books,
medical knowledge bases, encyclopedias, glossaries, and online information sources and web-
sites. We developed a dictionary in English with concepts, definitions and synonyms, and then
translated it to Spanish and Catalan to analyze the EMRs (S1 Table). Classes were annotated
with synonyms, both manually and in an automated way, making use of mappings to external
ontologies provided by the National Center for Biomedical Ontology [6]. For entity (word) rec-
ognition within a text, the dictionary was incorporated into the ProMiner software [7]. The on-
tology is freely available at Bioportal (http://purl.bioontology.org/ontology/MSO) and at the
Fraunhofer website: http://www.scai.fraunhofer.de/de/geschaeftsfelder/bioinformatik/
downloads.html
In a subsequent step, various “class-concepts” were used as keywords to search PubMed ab-
stracts in order to build a corpus that covers the MS domain: MS biomarkers, brain regions, di-
agnostic procedures, therapies, epidemiology, etiology, genetics, pathogenesis, stages,
symptoms, clinical trials, and risk factors (Fig. 1). For enrichment purposes, the training set
was analyzed for false-negative entities that were added to the MS Ontology terminology after
individual expert evaluation. Moreover, MS experts cross-checked the whole ontology and ad-
ditional expert knowledge was incorporated. See S1 Methods for details.
Analysis of MS concepts in PubMed abstracts and EMRs
To retrieve and analyze concepts from PubMed abstracts, the MS Ontology was integrated into
the SCAIView text-mining system (http://www.scaiview.com). SCAIView is a text-mining soft-
ware that is able to identify terms and connect them using dictionaries. The MS Ontology dic-
tionary is available: 1) as a hierarchy tree; 2) as a searchable tool using auto-completion; 3) by
highlighting results in documents (pdf); and 4) showing results in the “Entity View”. In order
to analyze EMRs, we linked the MS Ontology dictionary to the DrugBank dictionary to retrieve
drug usage information and to the Medical Subject Heading (MeSH) terms to identify co-mor-
bidities. The performance of the MS Ontology in comparison to manual searches in PubMed
was analyzed using F statistics as described elsewhere [5].
Results
Development and evaluation of the MS Ontology
The MS Ontology was developed using the standards from the National Center for Biomedical
Ontology and represent medical knowledge specific to MS. The MS Ontology used a hierarchy
MSOntology
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of concepts in the MS knowledge domain, including: 1) Clinical features, 2) Etiology, 3) Models
of MS, 4) Molecular mechanisms on pathways, 5) Molecular and cellular features, and 6) Social
and economic impact of MS (Fig. 1, see S1 Methods for details). We evaluated the MS Ontology
on the abstract test set, founding that the MS Ontology could automatically retrieve a wide
range of MS concepts (F = 0.73, see the example in S1 Fig.). The expert panel’s revision is con-
sidered to be a genuine evaluation for disease ontologies [8], and allowing this revision by ex-
perts in MS, we curated the ontology manually.
We designed three clinical or scientific queries (competency questions) that were defined by
the experts to evaluate the performance of the MS Ontology in returning appropriate informa-
tion regarding disease pathogenesis (question 1 and 2) and therapies (question 3). The ques-
tions were designed in order to relate at least 3 different but common concepts, a kind of
search strategy that manual PubMed searches use to provide few results (false negative) or
non-specific/inaccurate results (false positive) (see S1 Methods for details):
1. Return references linking brain atrophy and remyelination and MS.
2. Return references linking Myelin Oligodendrocyte Glycoprotein and antibody-mediated de-
myelination and MS.
3. Return references linking fingolimod and phase 3 clinical trials and RRMS.
To evaluate the queries, we compared documents returned by the MS Ontology with docu-
ments returned by “advance search” in PubMed (we used manual search in PubMed using key-
words and revised by an expert as a gold standard). We found that the MS Ontology obtained a
Figure 1. The MS Ontology. A) Basic formal ontology integration of MS Ontology; B) Extracted views of the MS Ontology showing the hierarchy of the
concepts; C) Source documents for each category used for creating the ontology.
doi:10.1371/journal.pone.0116718.g001
MSOntology
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lower ratio of false positive and false negative results than manual searching (Table 1). Never-
theless, the information retrieved from PubMed with the MS Ontology provided a structure on
the basis of the relationship between terms, allowing the hierarchy and logic of the evidence
found in scientific abstracts to be followed (Fig. 2). These results indicate that MS Ontology-
based information retrieval improved the chances of gaining more accurate (decreasing false
positive and negative results) and structured information compared to PubMed
advance searches.
Mining PubMed abstracts using MS Ontology
To validate the use of the MS Ontology as an automatic tool to obtain scientific information
from PubMed abstracts, we combined the MS Ontology dictionary with dictionaries of human
genes, proteins and pathway. To explore the association between MS and genetic predisposi-
tion, we retrieved the list of genes associated with MS susceptibility using the MS Ontology and
compared this list with the genes validated in GWAS studies identified by the expert search
[9, 10]. Through the automatic search of PubMed with the MS Ontology we retrieved up to
80% of the genes mentioned in such GWAS studies (S2 Table). Moreover, using the MS Ontol-
ogy we retrieved 13 genes (TMEM39A, ERAP1, KIF5A, DHCR7, CD226, TYK2, DEXI,
MYTIL, ZFP57, C7, SCIN, DPP6, PSMB9) that have been associated with MS in GWAS studies
[13, 14] but that were not mentioned even in the main text of the article but rather in other sec-
tions of the articles (e.g. tables, supplementary material, etc.). Therefore, the MS Ontology was
useful as an automated system to retrieve highly specific scientific information from a wide
knowledge area (e.g. genes associated with autoimmune diseases) without manual supervision.
As a second example, we used the MS Ontology in combination with the pathway dictionary
to analyze PubMed abstracts in order to generate maps that relate current disease-modifying
drugs (DMD) for MS to their molecular targets (receptors) and downstream pathways. We
compared our results with a search in the KEGG database (http://www.genome.jp) as the
Table 1. Results of competency questions evaluation using MS Ontology compared to manual
search on PubMed.
Question No. 1 2 3
# Documents retrieved by MS Ontology 26 9 27
• Validated documents (MS Ontology) 26 9 26
Speciﬁcity of MS Ontology 100% 100% 96%
# Documents retrieved by PubMed advanced search 0 3 1
• Validated documents (PubMed advance search) 0 2 1
# Documents retrieved by expert search in PubMed 18 11 14
• Validated documents (expert search) 15 9 12
• Sensitivity of MS Ontology 100% 100% 100%
Results are shown as the number of all retrieved documents and the “validated ones” based in manual
review of the documents by the expert in order to ensure they were covering the topics of the competency
questions. We deﬁne as the gold standard for calculating sensitivity, the expert search in PubMed using
key words (related with AND) and the manual revision of the abstracts. In order to calculate ‘Sensitivity’ and
‘Speciﬁcity’ of MS Ontology based searches, true positives are deﬁned as the number of ‘validated
documents’ retrieved by a MS Ontology based search; false positive are the number of documents
retrieved by MS Ontology based search but were not considered relevant in expert review and False
negatives are the number of documents retrieved by ‘expert based searches’ in PubMed but were not
retrieved by MS Ontology. See S1 Methods for details of the searches.
doi:10.1371/journal.pone.0116718.t001
MSOntology
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reference database for biological pathways. We found that KEGG only contains drug-target-
pathway information for inteferon-beta1a and teriflunomide, whereas the MS Ontology identi-
fied additional drug-target-pathway maps for MS therapies (Fig. 3). Such new drug-pathway
maps will require experimental validation and can be used as starting hypothesis for the analy-
sis of the biological effects of drugs in MS.
Automatic analysis of electronic medical records from MS patients using
MS Ontology
In order to assess the usefulness of MS Ontology to extract information from the EMRs of pa-
tients with MS, we used MS Ontology with the English dictionaries translated into Spanish and
Catalan, to mine the EMR of 624 MS patients. We focused on retrieving information regarding
the presence of co-morbidities and the use of drugs because these topics have been analyzed by
recent studies and will serve as reference [11–23]. Second, because even if this information can
Figure 2. Concepts identified using the MS Ontology in the competency questions. Figure shows the
concepts (in grey boxes) retrieved in the competency questions (search strategy) annotated by the MS
Ontology and linked to other MS Ontology concepts, indicating the PMID of the abstract from PubMed and
the type of interaction described in such abstract. A) references linking brain atrophy and CNS repair with
remyelination in MS; B) references linking Myelin Oligodendrocyte Glycoprotein (MOG) to antibody-mediated
demyelination; and C) references linking fingolimod tested as a drug for treatment of relapsing-remitting MS
in phase 3 clinical trials
doi:10.1371/journal.pone.0116718.g002
MSOntology
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be obtained straightforward from the EMR, the MS Ontology should be able to relate with
other concepts in MS. An example of two anonymized medical records on which the search for
drug usage and co-morbidities is shown in S2 Fig. Regarding drug usage by MS patients, we
found the frequency of DMD use was consistent with recent surveys in Europe, US and Canada
(Table 2, S3 Table) [11–15]. In terms of the use of symptomatic therapy, we observed a similar
high use of analgesics and benzodiazepines as it has been described previously [16–19]. We
also analyzed the presence of co-morbidities in the EMRs of MS patients using the MS Ontolo-
gy. Accordingly, we found a high frequency of CNS/psychiatric, cancer, cardiovascular, or met-
abolic diagnoses, in accordance with previous studies using other approaches, such as self-
registries, databases, etc. (Table 3, S4 Table) [20–23]. Overall, the MS Ontology was able to re-
trieve information from the EMR regarding drug usage and comorbidities, which is in agree-
ment with recent surveys in the field. Such information can be related with other clinical and
biological concepts with the use of the MS Ontology in order to generate new hypothesis for fu-
ture clinical research.
Figure 3. Drug-target-pathwaymap of MS drugs using MSOntology compared to KEGG database. A
search in the KEGG database (a database of molecular pathways and drugs), identified pathways associated
with interferon-beta and teriflunomide (box in the left). The automatic retrieval using MS Ontology identified
additional pathways for all current MS disease modifying therapies, including mitoxantrone, natalizumab,
azathioprine, laquinimod, simvastatin, levostatin, dimethyl-fumarate, rituximab and daclizumab and
their interactions.
doi:10.1371/journal.pone.0116718.g003
Table 2. Top 5-drug usage by patients with MS identiﬁed in the EMR.
No Disease modifying therapies %
1 Interferon-beta 43%
2 Glatiramer Acetate 17%
3 Natalizumab 7%
4 Fingolimod 7%
5 Rituximab 0.5%
No Symptomatic therapy %
1 Acetaminophen 18%
2 Aminosalicylic Acid 12%
3 Baclofen 9%
4 Lorazepam 5%
5 Diazepam 5%
doi:10.1371/journal.pone.0116718.t002
MSOntology
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Discussion
In this study we describe a new tool for automatic information retrieval in MS by developing
an ontology specific for MS. Applying an ontology-driven information mining approach that
models MS related concepts and hierarchies, enhances the quality of information searches. At
present, PubMed is the only "open access" engine available to search for MS related informa-
tion. Although, the search capacity of PubMed has increased tremendously in the last decade
(e.g advance search options), there is still a considerable effort demanded of users to obtain the
information in which they are interested in (e.g. search using "keywords" and manual review of
abstracts). By contrast, MS Ontology has the ability to answer all such queries. Additionally,
further information is obtained by linking the MS Ontology to other specific terminologies
within the text-mining software, such as other disease ontologies, drug dictionaries, pathway
information, or gene and protein dictionaries.
The applications presented here demonstrate some potential uses of the MS Ontology for
translational and clinical research in the field of MS. MS Ontology performed adequately when
compared with reference search engines (advanced searches of PubMed or of searches in the
KEGG database for pathway analysis). In addition, its application to the analysis of EMR exem-
plifies how text-mining can be performed with MS Ontology. Therefore, at present the MS On-
tology can only be used by MS researchers in studies that wish to exploit the exponential
growth in scientific literature that cannot be approached by manual searches in PubMed, and
the almost unexplored information contained in the EMRs (e.g Phenome wide association
studies (PheWAS)) [24]. We also envisage that this tool will be useful for clinicians interested
in analyzing health care strategies for their specific population of MS patients.
Table 3. Comorbidities diagnosed in patients with MS identiﬁed in the EMR.
No Disease class %
1 Nervous system diseases 31%
2 Neoplasms 14%
3 Musculoskeletal disorders 13%
4 Otorhinolaryngologic Diseases 10%
5 Eye diseases 7%
6 Mental disorder 7%
7 Eye disease 7%
8 Congenital, hereditary and neonatal diseases and abnormalities 5%
9 Cardiovascular diseases 5%
10 Immune system diseases 5%
11 Nutritional and metabolic disorders 5%
12 Respiratory tract diseases 4%
13 Skin and connective tissue diseases 4%
14 Female urogenital diseases 4%
15 Endocrine system diseases 4%
16 Digestive system diseases 4%
17 Bacterial infections and Mycoses 4%
18 Behavior and behavioral mechanisms 3%
19 Male urogenital diseases 3%
20 Viral diseases 2%
21 Hemic and lymphatic diseases 2%
22 Parasitic diseases 0.6%
doi:10.1371/journal.pone.0116718.t003
MSOntology
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In recent years, the benefits of ontologies have become evident in data management, inte-
gration and processing, in both the biological and medical domain. In the case of AD [5], the
development of a specific ontology was critical because the amount of research conducted
every year is significantly higher than that of other diseases such as MS, epilepsy or Parkinson
disease. Moreover, the epidemiology of dementia is reaching epidemic proportions, implying
that the analysis of EMRs will provide access to millions of records. While MS can be consid-
ered a specialized or “niche disease”, the number of scientific studies and cases in EMRs is too
large to explore all this information manually, as is done currently. For this reason, the use of a
specific ontology will be very beneficial for clinical and translational research into MS [25].
However, we need to bear in mind that generating more information, even if it is of high quali-
ty, does not necessarily mean creating more knowledge. Computational based reasoning sys-
tems (clinical decision support systems) are currently being developed, and they may represent
the link between automatic information retrieval, research and clinical decision making process
[26, 27].
In order to analyze the huge amount of information that has been generated to date, and
that can be retrieved with tools such as ontologies, advanced statistical or computational tools
must be used in systems medicine approaches, employing neuronal networks, decision trees or
network analysis [2, 3]. For example, recent network analysis of co-morbidities has provided
significant insights into the relationship between genes, proteins, pathways and chronic dis-
eases [28, 29]. Similarly, network analysis of drug usage has identified drug combinations that in-
crease or decrease the risk of side effects [30]. These approaches are based on information
retrieval from medical databases (Medicare, FDA adverse events database) containing informa-
tion on millions of patients. However, it usefulness is limited in less prevalent diseases such as
MS. Accordingly, the use of a specific ontology for MS may be particularly useful to extract in-
formation from EMRs of MS patients, and from clinical and molecular databases, thereby max-
imizing the identification of new associations between risk factors, molecules, therapies and
clinical phenotypes.
One of the great advantages of developing the MS Ontology is that it can be used to extract
information from patients with MS contained in the EMRs. However, the analysis of EMRs
represents a significant challenge [31, 32]. EMRs contain highly structured information, such
as diagnostic codes, but also plain text as in the natural language from physician’s notes. The
health systems in different countries also influence the information structure of EMRs. For this
reason, there is a tendency to overcode in health systems in which reimbursement is based on
coding (e.g. US, Taiwan), whereas there is a tendency to undercode in health systems where re-
imbursement is based in population coverage (e.g. Europe). In order to avoid the undercoding
in the Spanish system, we included ICD-9 codes in our search, but also search terms such as
“Multiple Sclerosis” or “demyelinating diseases”. The manual review of the EMRs retrieved re-
vealed that MS Ontology was very efficient in identifying MS cases. Regarding the analysis of
natural language from clinical notes using the MS Ontology, we noticed that the search system
is sensitive to typographic errors, misspelling, abbreviations and synonyms. For this reason, we
updated the MS Ontology dictionary in order to account for such factors, subsequently obtain-
ing greater accuracy. As an example of the mining of EMRs from MS patients, Harvard’s re-
searchers searched EMRs for the estimation of disability (EDSS) and brain atrophy based on
the clinical information fromMS patients followed in non-specialized MS centers [33]. Current
efforts are undergoing in order to make use of EMRs for retrieving information fromMS cases,
revealing the challenges faced with this approach [34, 35].
Although one can consider that retrieving drug usage in patients with MS is straightforward
because these drugs are highly regulated, the true value will come from performing analysis of
EMRs from thousand of patients being treated with immunomodulatory drugs in order to
MSOntology
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understand the patterns of prescription, frequency of adverse-events and to some degree, the
efficacy of the therapies (virtual clinical trials). Furthermore, such analyses can be used to un-
derstand the role of drugs in disease predisposition at the population level or by using drug pre-
scription as a proxy of co-morbidities (e.g. antibiotics = infection).
In summary, we provide here a new tool for clinical and translational research into MS,
which can be used to extract information from the scientific literature, databases and EMRs.
Making use of this ontology, we have shown that it is possible to identify new associations be-
tween risk factors, molecules, therapies and pathways, and to identify clinical associations with
other diseases and therapies. The use of this approach will provide the opportunity to exploit
the huge amount of data currently generated by scientific research and clinical care, improving
our understanding of MS. However, new computational tools to generate knowledge from this
vast amount of information will be required in order to fully benefit from this approach.
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